Receiveable Turnover: An accounting measure used to quantify a firm's effectiveness in extending credit as well as collecting debts. Calculated as: Total Revenues / Accounts Receivable
Neurocrine Biosciences, Inc. (NBIX) had Receiveable Turnover of 1.09 for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$794.90M |
|
$209.50M |
|
$14.00M |
|
$780.90M |
|
$555.90M |
|
$239.00M |
|
$52.80M |
|
$291.80M |
|
$261.20M |
|
$209.50M |
|
$209.50M |
|
$209.50M |
|
$170.27M |
|
$239.00M |
|
$246.70M |
|
99.40M |
|
102.50M |
|
$2.11 |
|
$2.04 |
|
| Balance Sheet Financials | |
$2.16B |
|
$97.30M |
|
$2.11B |
|
$4.27B |
|
$638.00M |
|
-- |
|
$624.10M |
|
$1.26B |
|
$3.00B |
|
$2.97B |
|
$3.00B |
|
99.70M |
|
| Cash Flow Statement Financials | |
$394.30M |
|
$-211.50M |
|
$-75.60M |
|
$241.00M |
|
$348.20M |
|
$107.20M |
|
$159.30M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.38 |
|
-- |
|
-- |
|
-- |
|
-- |
|
98.24% |
|
30.07% |
|
30.07% |
|
-- |
|
36.71% |
|
26.36% |
|
$357.90M |
|
-- |
|
-- |
|
-- |
|
0.19 |
|
0.20 |
|
|
Receiveable Turnover |
1.09 |
82.43 |
|
6.97% |
|
7.06% |
|
4.91% |
|
6.97% |
|
$30.13 |
|
$3.49 |
|
$3.85 |
|